* EnzyMed Inc., of Iowa City, which uses enzyme-based combinatorial chemistry to create libraries oforganic molecules, entered a research collaboration withDuPont Agricultural Products, a subsidiary of theWilmington, Del.-based E.I. Du Pont & Co.. Terms werenot disclosed.

* GenPharm International Inc., of Mountain View,Calif., sold its transgenic laboratory products division toTaconic Farms Inc., of Germantown, N.Y. Terms werenot disclosed. The sale includes eight GenPharmtransgenic animal models, such as the TSG-p53transgenic mouse, which is deficient in the p53 tumorsuppressor gene.

* Interneuron Pharmaceuticals Inc., of Lexington,Mass., said a double-blind, placebo-controlled study inthe U.K. of melatonin showed low doses of the drughelped overcome insomnia and improved subjects qualityof sleep. Melatonin is a hormone secreted by the pinealgland in the brain and is involved in regulating sleepingand walking.

* Progenitor Inc., of Columbus, Ohio, licensed fromVanderbilt University in Nashville, Tenn., a patent for thedevelopmental endothelial locus-1 gene, which expressesa protein thought to be involved in the growth ofendothelial cells and blood vessels. Vanderbilt willreceive royalties on any products. Progenitor is asubsidiary of Interneuron Pharmaceuticals Inc., ofLexington, Mass.

* Sepracor Inc., of Marlborough, Mass., said OFDPartners L.P., of New York, exercised warrants topurchase 793,650 Sepracor shares for $5 million.

* The Immune Response Corp., of Carlsbad, Calif.,received FDA clearance to test its psoriasis therapy in aPhase II trial.

* Protein Design Labs Inc., of Mountain View, Calif.,began a Phase II trials of its monoclonal antibody fortreatment of cytomegalovirus (CMV) retinitis in AIDSpatients. The studies of the human anti-CMV antibodyare being conducted in association with the NationalInstitute of Allergy and Infectious Diseases. In addition,Johns Hopkins University and the National Eye Institutewill conduct a separate Phase II/III trial with themonoclonal antibody for CMV in AIDS patients.

(c) 1997 American Health Consultants. All rights reserved.

No Comments